查詢結果分析
相關文獻
- 淺談表皮溶解症臨床治療
- Sympathetic Ophthalmia Associated with Cyclitis: Case Report
- The Clinical Experience of Cyclosporin A Therapy in Primary Glomerulonephritis
- Cyclosporine--Induced Gingival Overgrowth Case Report and Literature Review
- 環孢靈與乾癬之皮膚試驗
- Cyclosporine-Induced Encephalopathy in a Patient with Relapsed Acute Myeloid Leukemia Treated with Unrelated Allogeneic Bone Marrow Transplantation
- New Approaches to Clinical Transplantation Immunosuppression: Immunosuppressive Agents of the New Millennium
- Successful Treatment of Idiopathic Membranoproliferative Glomerulonephritis Type I with Combined Methylprednisolone Pulse, Cyclosporin A and Angiotensin Ⅱ Antagonist
- 重症肌無力危象的加護照顧
- 中藥對CYCLOSPORIN之藥品動力學影響
頁籤選單縮合
題名 | 淺談表皮溶解症臨床治療=The Ttreatment of Toxic Epidermal Necrolysis |
---|---|
作者 | 楊士磐; 簡素玉; 童玟津; 簡素玉; | 書刊名 | 藥學雜誌 |
卷期 | 33:3=132 2017.09[民106.09] |
頁次 | 頁60-65 |
分類號 | 415.681 |
關鍵詞 | 毒性表皮溶解症; 環孢靈; 靜脈免疫球蛋白; Toxic epidermal necrolysis; Cyclosporine; Intravenous immune globulin; |
語文 | 中文(Chinese) |
中文摘要 | 史蒂文強生氏症候群 (Stevens-Johnson syndrome, SJS) 和毒性表皮溶解症 (toxic epidermal necrolysis , TEN),大部份是由藥物引起,患者被確診後應立即入院治療與 評估,轉至加護病房或燒燙傷中心,目前對於 TEN 並未找出完整且預後良好的治療 模式,治療共識為先停止可能的致病藥物、給予適當的支持療法與減緩疾病進展,並 預防日後的引起的併發症。除盡早停用致病藥物外,應注意相似化學結構的致病藥物 間也可能存在的交叉反應。根據目前有限的研究,對於 TEN 臨床預後的治療可能有 助益為 intravenous immune globulin、plasmapheresis;其他如類固醇、cyclosporine 因 療效爭議較大,臨床應小心使用,謹慎評估利弊;thalidomide、TNF-α inhibitor 與 cyclophosphamide 於臨床上未被證明有效,不建議使用。 |
英文摘要 | Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe mucocutaneous adverse reactions, most commonly triggered by medications. When patients were diagnosed TEN should be immediately admitted to treatment and assessment, transferred to the intensive care unit or burn center, the current TEN did not find a treatment guideline , the consensus is to stop the possible pathogenic drugs, appropriate supportive therapy and slow disease progression and prevent future complications. In addition to early discontinuation of pathogenic drugs, we must pay attention to the cross-reaction between similar chemical structure of the causative drug. We suggest not using thalidomide,TNF-α inhibitor and cyclophosphamide for TEN, and the intravenous immune globulin, plasmapheresis may be possible benefit for the TEN. The use of systemic and cyclosporine in patients with TEN remain controversial. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。